Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06231264

Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative Colitis

The aim of this study was to evaluate the efficacy and safety of transcutaneous electrical acustimulation in patients with mild to moderate ulcerative colitis.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Honghui hospital, Xi'an, Shaanxi, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Ulcerative colitis diagnosed for at least 3 mouths.
  • Mayo score 4-10, Mayo endoscopic score 2-3 points
  • Resistant to at least one type of medical treatments

Exclusion criteria

  • Treatment-naive ulcerative colitis (no previous treatment)
  • Acute severe ulcerative colitis
  • Previous surgical treatment or severe colitis at imminent risk of surgery infective colitis
  • Other systemic diseases
  • Pregnancy and lactation
  • Allergic to the electrode patch

Treatment and study plan

transcutaneous electrical acustimulation at treatment sites

Device

A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the treatment site. The precise stimulating sites are not described upon registration to reduce unblinding risk.

Other names: TEA

transcutaneous electrical acustimulation at sham sites

Device

A transcutaneous electrical stimulator (TEA) device applies a mild electric stimulation through the skin, similar to acupuncture at the sham treatment sites. The precise stimulating sites are not described upon registration to reduce unblinding risk.

Other names: sham-TEA

Primary outcomes

  1. Clinical response

    Time frame: 8 weeks

    decrease of ≥3 points and ≥30% from baseline mayo score and decrease of ≥1 point in rectal bleeding subscore or absolute rectal bleeding subscore ≤ 1

Secondary outcomes

  1. Change from baseline in the Mayo score

    Time frame: 8 weeks

    Mayo score at 8 week minus the Mayo score at baseline. The range of Mayo score is 0-12, and higher scores mean worse outcome.

  2. Endoscopic remission

    Time frame: 8 weeks

    defined as Mayo endoscopic score ≤ 1

  3. Clinical remission

    Time frame: 8 weeks

    overall score ≤2 [and no individual subscore >1]

  4. Symptomatic remission

    Time frame: 2, 4, 6, and 8 weeks

    Stool frequence subscore = 0 (or = 1 with a ≥ 1-point decrease from baseline) and rectal bleeding subscore = 0

  5. Fecal calprotectin

    Time frame: 4 and 8 weeks

    fecal sample

  6. erythrocyte sedimentation rate

    Time frame: 4 and 8 weeks

    blood sample

  7. C reactive protein

    Time frame: 4 and 8 weeks

    blood sample

  8. pancreatic polypeptide

    Time frame: 4 and 8 weeks

    blood sample

  9. norepinephrine

    Time frame: 4 and 8 weeks

    blood sample

  10. acetyl choline

    Time frame: 4 and 8 weeks

    blood sample

  11. acetyl choline

    Time frame: 8 weeks

    Intestinal mucosal tissue sample

  12. alpha7 nicotinic acetylcholine receptor

    Time frame: 8 weeks

    Intestinal mucosal tissue sample

  13. Inflammatory Bowel Disease Questionnaire Score

    Time frame: 4 and 8 weeks

    The range of Inflammatory Bowel Disease Questionnaire Score is 32-224, and higher scores mean worse outcome

  14. Hospital Anxiety and Depression scale score

    Time frame: 4 and 8 weeks

    anxious depression. The range of Hospital Anxiety and Depression scale score is 0-21, and higher scores mean worse outcome.

  15. Pittsburgh sleep quality index

    Time frame: 4 and 8 weeks

    The range of Pittsburgh sleep quality index is 0-21, and higher scores mean worse outcome.

  16. autonomic profile characteristics

    Time frame: 4 and 8 weeks

    heart rate variability indicating sympathetic and parasympathetic activity

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Xijing Hospital

Other

Registry information

Official study title

A Multicenter Randomized Controlled Trial of Transcutaneous Electrical Acustimulation in the Treatment of Mild to Moderate Ulcerative Colitis

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Jan 30, 2024
Registry last updated
May 25, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.